20.500.12556/DiRROS-13873 The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever : a systematic review of the literature Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1[beta], has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment. familial Mediterranean fever -- therapy -- review monoclonal antibodies canakinumab anti-IL1 therapy družinska mediteranska vročica -- terapija -- pregled literature monoklonska protitelesa canakinumab anti-IL1 terapija true false true Dove Press Angleški jezik Ni določen © 2020 Kacar et al. Neznano 2021-04-08 14:43:47 2021-04-08 14:43:47 2022-08-19 03:37:19 0000-00-00 00:00:00 2020 0 Nova Zelandija 0 Nasl. z nasl. zaslona; Opis vira z dne 1. 4. 2021; str. 141-149 Vol. 13 9 Mar. 2020 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 577.2 1178-7031 10.2147/JIR.S206204 58075139 RAZ_Kacar_Mark_i2020.pdf RAZ_Kacar_Mark_i2020.pdf 1 D1827B5AB0D1319B2A600CD477DADF9E 66f83767c7cb8b45ec3f5a2e2bc9d313d3f20a21a144a4a60e28a606609297a3 82c688aa-17b6-11ed-b6b8-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=17112 https://www.dovepress.com/getfile.php?fileID=56642 1 https://dirros.openscience.si/Dokument.php?lang=slv&id=17111 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0